SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

PROFIT WARNING

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company wishes to inform the shareholders and potential investors of the Company that, based on the unaudited management accounts currently available to the Group and a preliminary estimate by the Company's management, the Group is expected to record a loss and total comprehensive income attributable to equity shareholders of the Company of approximately RMB590 million for the six months ended 30 June 2026, representing an increase in loss of approximately RMB540 million compared to the loss and total comprehensive income attributable to equity shareholders of the Company of approximately RMB50 million recorded in the corresponding period of last year. The expected loss was primarily attributable to the easing of the influenza epidemic in the first half of 2026, which resulted in a significant year-on-year decrease in the sales volume of Kewei, the Group's core product and a primary drug for influenza treatment.

As of the date of this announcement, Olorigliflozin capsule, a Class I innovative drug independently developed by the Group, was approved for marketing in the PRC; the Insulin Degludec Injection independently developed by the Group was approved for marketing in the PRC, establishing a comprehensive insulin product matrix spanning second- to fourth-generation products; and the Insulin Glargine Injection independently developed by the Group has obtained marketing approval from the U.S. Food and Drug Administration and achieved overseas commercial shipment. In the future, while continuously consolidating the commercialisation layout of its existing product pipelines, the Group will focus on its strategy of innovation and international development, further accelerating the research, development, and commercialisation of key products, such as innovative drugs and biologics, to continuously enrich its product pipeline and steadily advance the international layout of its products and markets.

The Company is still in the process of finalising its interim results announcement for the six months ended 30 June 2026. The information contained in this announcement is solely based on a preliminary assessment of the Company's management with the unaudited management accounts of the Group for the six months ended 30 June 2026 and other information currently available to the Company, which has not been reviewed or audited by the auditors of the Company. Details of the financial information of the Group for the six months ended 30 June 2026 will be disclosed in the interim results announcement of the Company, which is expected to be published on 31 August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
24 August 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.